DE10209985A1 - Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze - Google Patents

Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Info

Publication number: DE10209985A1
Authority: DE; Germany
Prior art keywords: methyl; pharmaceutical composition; acid; composition according; optionally
Prior art date: 2002-03-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE10209985A

Other languages

German (de)

English (en)

Inventor

Ulrich Brauns

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Original Assignee

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-07

Filing date

2002-03-07

Publication date

2003-09-25

2002-03-07 Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG

2002-03-07 Priority to DE10209985A priority Critical patent/DE10209985A1/de

2003-03-03 Priority to UA20041008096A priority patent/UA81760C2/uk

2003-03-03 Priority to SI200332126T priority patent/SI1870100T1/sl

2003-03-03 Priority to DK03743368.7T priority patent/DK1485094T4/da

2003-03-03 Priority to UAA200708221A priority patent/UA95601C2/uk

2003-03-03 Priority to ES07115663T priority patent/ES2380704T3/es

2003-03-03 Priority to HK05110948.7A priority patent/HK1078792B/xx

2003-03-03 Priority to PL370517A priority patent/PL210862B1/pl

2003-03-03 Priority to JP2003572573A priority patent/JP3866715B2/ja

2003-03-03 Priority to MEP-2008-507A priority patent/ME00325B/me

2003-03-03 Priority to EA200401136A priority patent/EA009664B1/ru

2003-03-03 Priority to CA2476054A priority patent/CA2476054C/en

2003-03-03 Priority to ES03743368T priority patent/ES2390661T5/es

2003-03-03 Priority to CN200910149806A priority patent/CN101632668A/zh

2003-03-03 Priority to EP03743368.7A priority patent/EP1485094B2/de

2003-03-03 Priority to PT07115663T priority patent/PT1870100E/pt

2003-03-03 Priority to BRPI0306559A priority patent/BRPI0306559B8/pt

2003-03-03 Priority to SI200332190T priority patent/SI1485094T2/sl

2003-03-03 Priority to KR1020047013919A priority patent/KR101005716B1/ko

2003-03-03 Priority to YU79204A priority patent/RS52088B/sr

2003-03-03 Priority to NZ535663A priority patent/NZ535663A/en

2003-03-03 Priority to SG200504113-2A priority patent/SG146435A1/en

2003-03-03 Priority to PL394601A priority patent/PL212566B1/pl

2003-03-03 Priority to AT07115663T priority patent/ATE540943T1/de

2003-03-03 Priority to PT03743368T priority patent/PT1485094E/pt

2003-03-03 Priority to HRP20040807AA priority patent/HRP20040807B1/hr

2003-03-03 Priority to IL16386303A priority patent/IL163863A0/xx

2003-03-03 Priority to PCT/EP2003/002141 priority patent/WO2003074056A1/de

2003-03-03 Priority to AU2003210400A priority patent/AU2003210400B8/en

2003-03-03 Priority to DK07115663.2T priority patent/DK1870100T3/da

2003-03-03 Priority to EP07115663A priority patent/EP1870100B1/de

2003-03-03 Priority to NZ546367A priority patent/NZ546367A/en

2003-03-03 Priority to CNB038054736A priority patent/CN100528157C/zh

2003-03-03 Priority to MXPA04008542A priority patent/MXPA04008542A/es

2003-03-05 Priority to PE2003000211A priority patent/PE20030889A1/es

2003-03-05 Priority to MYPI20030780A priority patent/MY143734A/en

2003-03-06 Priority to UY27694A priority patent/UY27694A1/es

2003-03-06 Priority to TW092105051A priority patent/TWI293879B/zh

2003-03-06 Priority to US10/383,198 priority patent/US20030181488A1/en

2003-03-07 Priority to ARP030100779A priority patent/AR042861A1/es

2003-09-25 Publication of DE10209985A1 publication Critical patent/DE10209985A1/de

2004-06-07 Priority to NO20042361A priority patent/NO326918B1/no

2004-07-29 Priority to ZA2004/06071A priority patent/ZA200406071B/en

2004-09-01 Priority to IL163863A priority patent/IL163863A/en

2004-09-30 Priority to EC2004005331A priority patent/ECSP045331A/es

2004-10-06 Priority to CO04099830A priority patent/CO5611149A2/es

2006-05-05 Priority to US11/381,890 priority patent/US9925174B2/en

2006-08-10 Priority to JP2006218435A priority patent/JP2007056018A/ja

2006-08-10 Priority to JP2006218436A priority patent/JP4953727B2/ja

2008-03-12 Priority to NO20081304A priority patent/NO332209B1/no

2009-06-26 Priority to ARP090102391A priority patent/AR072385A2/es

2009-09-29 Priority to CL2009001915A priority patent/CL2009001915A1/es

2010-11-17 Priority to IL209368A priority patent/IL209368A/en

2012-04-09 Priority to CY20121100346T priority patent/CY1112796T1/el

2012-06-20 Priority to LU92025C priority patent/LU92025I2/fr

2012-06-29 Priority to DE201212000047 priority patent/DE122012000047I1/de

2012-07-10 Priority to CY2012020C priority patent/CY2012020I1/el

2012-09-28 Priority to CY20121100894T priority patent/CY1113158T1/el

2012-12-14 Priority to CY2012031C priority patent/CY2012031I1/el

2012-12-19 Priority to LU92117C priority patent/LU92117I2/fr

2013-01-02 Priority to NO2013001C priority patent/NO2013001I2/no

2014-09-18 Priority to US14/489,892 priority patent/US20150005350A1/en

2018-04-05 Priority to US15/946,096 priority patent/US20180221359A1/en

2019-04-10 Priority to US16/380,161 priority patent/US20190231766A1/en

2019-11-25 Priority to US16/694,091 priority patent/US20200085807A1/en

Status Withdrawn legal-status Critical Current

Links

150000007524 organic acids Chemical class 0.000 title claims abstract description 23
-1 ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino Chemical group 0.000 title abstract description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 title abstract 2
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 title 1
229940122388 Thrombin inhibitor Drugs 0.000 title 1
239000008203 oral pharmaceutical composition Substances 0.000 title 1
239000003868 thrombin inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
239000008188 pellet Substances 0.000 claims abstract description 16
239000003795 chemical substances by application Substances 0.000 claims abstract description 13
239000011230 binding agent Substances 0.000 claims abstract description 11
239000000049 pigment Substances 0.000 claims abstract description 11
239000004014 plasticizer Substances 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 11
239000011248 coating agent Substances 0.000 claims abstract description 10
238000000576 coating method Methods 0.000 claims abstract description 10
239000006185 dispersion Substances 0.000 claims abstract description 10
238000011049 filling Methods 0.000 claims abstract description 9
239000007902 hard capsule Substances 0.000 claims abstract description 7
238000001125 extrusion Methods 0.000 claims abstract description 4
238000005563 spheronization Methods 0.000 claims abstract description 4
229920003169 water-soluble polymer Polymers 0.000 claims abstract description 4
238000001035 drying Methods 0.000 claims abstract description 3
238000005453 pelletization Methods 0.000 claims abstract description 3
239000011162 core material Substances 0.000 claims description 38
239000004480 active ingredient Substances 0.000 claims description 34
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 25
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 22
238000000034 method Methods 0.000 claims description 22
235000002906 tartaric acid Nutrition 0.000 claims description 22
239000011975 tartaric acid Substances 0.000 claims description 22
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
229920000084 Gum arabic Polymers 0.000 claims description 17
239000000205 acacia gum Substances 0.000 claims description 17
235000010489 acacia gum Nutrition 0.000 claims description 17
239000013543 active substance Substances 0.000 claims description 16
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
229920000642 polymer Polymers 0.000 claims description 12
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
241000978776 Senegalia senegal Species 0.000 claims description 9
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
239000002253 acid Chemical class 0.000 claims description 9
229920001577 copolymer Polymers 0.000 claims description 9
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 8
229920000609 methyl cellulose Polymers 0.000 claims description 8
235000010981 methylcellulose Nutrition 0.000 claims description 8
KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims description 7
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
239000001530 fumaric acid Substances 0.000 claims description 6
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 5
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
235000003704 aspartic acid Nutrition 0.000 claims description 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
235000015165 citric acid Nutrition 0.000 claims description 3
235000011087 fumaric acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
239000001630 malic acid Substances 0.000 claims description 3
235000011090 malic acid Nutrition 0.000 claims description 3
235000005985 organic acids Nutrition 0.000 claims description 3
239000001384 succinic acid Substances 0.000 claims description 3
229920001059 synthetic polymer Polymers 0.000 claims description 3
238000010276 construction Methods 0.000 claims description 2
MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 claims 2
HVWNFJWGUPRPGC-UHFFFAOYSA-N 3-[[2-[[4-[(e)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C(/N)=N/C(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N1C HVWNFJWGUPRPGC-UHFFFAOYSA-N 0.000 claims 1
239000002612 dispersion medium Substances 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 24
239000000654 additive Substances 0.000 abstract 1
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 abstract 1
238000005469 granulation Methods 0.000 abstract 1
230000003179 granulation Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000454 talc Substances 0.000 description 14
235000012222 talc Nutrition 0.000 description 14
229910052623 talc Inorganic materials 0.000 description 14
150000001875 compounds Chemical class 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
239000002775 capsule Substances 0.000 description 11
238000003756 stirring Methods 0.000 description 10
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
229960005019 pantoprazole Drugs 0.000 description 9
244000171897 Acacia nilotica subsp nilotica Species 0.000 description 8
239000001863 hydroxypropyl cellulose Substances 0.000 description 7
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
238000011282 treatment Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000013078 crystal Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
241000196324 Embryophyta Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
238000007605 air drying Methods 0.000 description 4
239000001923 methylcellulose Substances 0.000 description 4
239000008213 purified water Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
206010025476 Malabsorption Diseases 0.000 description 3
208000004155 Malabsorption Syndromes Diseases 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
229960000288 dabigatran etexilate Drugs 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000012798 spherical particle Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
238000005299 abrasion Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000001087 glyceryl triacetate Substances 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
239000001034 iron oxide pigment Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
229960002622 triacetin Drugs 0.000 description 2
239000001069 triethyl citrate Substances 0.000 description 2
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
235000013769 triethyl citrate Nutrition 0.000 description 2
230000036325 urinary excretion Effects 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
UITNIDFEANEWPC-UHFFFAOYSA-N ethyl 3-(pyridin-2-ylamino)propanoate Chemical compound CCOC(=O)CCNC1=CC=CC=N1 UITNIDFEANEWPC-UHFFFAOYSA-N 0.000 description 1
SEGHHPAKTYKSLB-UHFFFAOYSA-N ethyl 3-[[2-[[4-[(hexoxycarbonylhydrazinylidene)methyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate Chemical compound C1=CC(C=NNC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C SEGHHPAKTYKSLB-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000009938 salting Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DE10209985A 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze Withdrawn DE10209985A1 (de)

Priority Applications (64)

Application Number	Priority Date	Filing Date	Title
DE10209985A DE10209985A1 (de)	2002-03-07	2002-03-07	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
UA20041008096A UA81760C2 (uk)	2002-03-07	2003-03-03	Фармацевтична композиція для перорального застосування етилового ефіру 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1-метил-1н-бензімідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти та спосіб її одержання
SI200332126T SI1870100T1 (sl)	2002-03-07	2003-03-03	Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
DK03743368.7T DK1485094T4 (da)	2002-03-07	2003-03-03	Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
UAA200708221A UA95601C2 (uk)	2002-03-07	2003-03-03	Метансульфонат етилового ефіру 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1метил-1н-бензимідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти та фармацевтична композиція, яка його містить
ES07115663T ES2380704T3 (es)	2002-03-07	2003-03-03	Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
HK05110948.7A HK1078792B (en)	2002-03-07	2003-03-03	Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
PL370517A PL210862B1 (pl)	2002-03-07	2003-03-03	Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji
JP2003572573A JP3866715B2 (ja)	2002-03-07	2003-03-03	３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態
MEP-2008-507A ME00325B (me)	2002-03-07	2003-03-03	Oblik za oralnu primjenu etilestra 3-[(2-{[4-(heksiloksikarbonjlaminoimino-metil)-fenilamino]-metil}-1-metil-ih-benzimidazol-5-carbonil)-piridin- 2-yl-amino]-propionsk kisjeline i njihovih soli
EA200401136A EA009664B1 (ru)	2002-03-07	2003-03-03	Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
CA2476054A CA2476054C (en)	2002-03-07	2003-03-03	Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
ES03743368T ES2390661T5 (es)	2002-03-07	2003-03-03	Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales
CN200910149806A CN101632668A (zh)	2002-03-07	2003-03-03	口服药物组合物
EP03743368.7A EP1485094B2 (de)	2002-03-07	2003-03-03	Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
PT07115663T PT1870100E (pt)	2002-03-07	2003-03-03	Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo
BRPI0306559A BRPI0306559B8 (pt)	2002-03-07	2003-03-03	composição farmacêutica para aplicação oral para mesilato de etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seu processo de preparação
SI200332190T SI1485094T2 (sl)	2002-03-07	2003-03-03	Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli
KR1020047013919A KR101005716B1 (ko)	2002-03-07	2003-03-03	３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
YU79204A RS52088B (sr)	2002-03-07	2003-03-03	Oblik za oralnu primenu etilestra 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionske kiseline i njegovih soli
NZ535663A NZ535663A (en)	2002-03-07	2003-03-03	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
SG200504113-2A SG146435A1 (en)	2002-03-07	2003-03-03	Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl- amino] propionic acid ethyl ester to be administered orally
PL394601A PL212566B1 (pl)	2002-03-07	2003-03-03	Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego
AT07115663T ATE540943T1 (de)	2002-03-07	2003-03-03	3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
PT03743368T PT1485094E (pt)	2002-03-07	2003-03-03	Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais
HRP20040807AA HRP20040807B1 (hr)	2002-03-07	2003-03-03	Oblik etil estera 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]-propionske kiseline i njegovih soli za oralnu aplikaciju
IL16386303A IL163863A0 (en)	2002-03-07	2003-03-03	Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
PCT/EP2003/002141 WO2003074056A1 (de)	2002-03-07	2003-03-03	Oral zu applizierende darreichungsform für 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen salze
AU2003210400A AU2003210400B8 (en)	2002-03-07	2003-03-03	Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-imino -methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
DK07115663.2T DK1870100T3 (da)	2002-03-07	2003-03-03	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester-methansulfonat
EP07115663A EP1870100B1 (de)	2002-03-07	2003-03-03	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester Methansulfonat
NZ546367A NZ546367A (en)	2002-03-07	2003-03-03	Methanesulphonate salt of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate to be administered orally
CNB038054736A CN100528157C (zh)	2002-03-07	2003-03-03	3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型
MXPA04008542A MXPA04008542A (es)	2002-03-07	2003-03-03	Forma de administracion para aplicacion oral, de ester etilico de acido 3-[(2- {[4 -(hexiloxicarbonilamino -imino-metil) -finilamino] -metil}-1 -metil- 1h-bencimidazol -5-carbonil) -piridin-2 -il-amino]- propionico y sales de la misma.
PE2003000211A PE20030889A1 (es)	2002-03-07	2003-03-05	Forma de presentacion para administracion por via oral, para ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil} -1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino] - propionico y sus sales
MYPI20030780A MY143734A (en)	2002-03-07	2003-03-05	Administration form for the oral application of 3-[(2-<[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl>-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
UY27694A UY27694A1 (es)	2002-03-07	2003-03-06	Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.
TW092105051A TWI293879B (en)	2002-03-07	2003-03-06	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino -imino -methyl)-phenylamion]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US10/383,198 US20030181488A1 (en)	2002-03-07	2003-03-06	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
ARP030100779A AR042861A1 (es)	2002-03-07	2003-03-07	Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales
NO20042361A NO326918B1 (no)	2002-03-07	2004-06-07	Farmasoytisk preparat og fremgangsmate for fremstilling derav.
ZA2004/06071A ZA200406071B (en)	2002-03-07	2004-07-29	Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-methyl)-pheny-lamino -methyl-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]propionic acid ethyl ester to be administered orally
IL163863A IL163863A (en)	2002-03-07	2004-09-01	Pharmaceutical composition for oral administration of 3-[(2 -{[4- (hexyloxycarbonylamino- imino- methyl)-phenylamino]methyl}-1- methyl-1h- benzimidazol-5- carbonyl)- pyridin- 2- yl- amino] propionic acid ethyl ester
EC2004005331A ECSP045331A (es)	2002-03-07	2004-09-30	Forma de presentación para administración por vía oral, para éster etílico de ácido 3?[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-?bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico y sus sales
CO04099830A CO5611149A2 (es)	2002-03-07	2004-10-06	Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com
US11/381,890 US9925174B2 (en)	2002-03-07	2006-05-05	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
JP2006218435A JP2007056018A (ja)	2002-03-07	2006-08-10	３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル又はその塩を含む経口投与用医薬組成物
JP2006218436A JP4953727B2 (ja)	2002-03-07	2006-08-10	３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルメタンスルホン酸塩及びそれを含む医薬組成物
NO20081304A NO332209B1 (no)	2002-03-07	2008-03-12	Etyl-3-[(2-{[4-(heksyloksykarbonyl¬amino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]-propionat- metansulfonat
ARP090102391A AR072385A2 (es)	2002-03-07	2009-06-26	Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico y composicion farmaceutica para administracion por via oral que lo contiene
CL2009001915A CL2009001915A1 (es)	2002-03-07	2009-09-29	Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexilcarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico; util como antitrombotico (divisional de la solicitud cl 425-2003).
IL209368A IL209368A (en)	2002-03-07	2010-11-17	Ethylsulfonate Salt of Ethyl 3 - [(2– {4– (xyloxycarbonylamino – amino – methyl) –phenylamino] –methyl} –1 – methyl – H1– benzamideimzole – 5 – carbonyl) –pyridine – 2 – ile-amino] propionate and preparation Pharmacy containing it
CY20121100346T CY1112796T1 (el)	2002-03-07	2012-04-09	Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβοονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας
LU92025C LU92025I2 (fr)	2002-03-07	2012-06-20	Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
DE201212000047 DE122012000047I1 (de)	2002-03-07	2012-06-29	3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino{-propionsaure-ethylester Methansulfonat.
CY2012020C CY2012020I1 (el)	2002-03-07	2012-07-10	Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας
CY20121100894T CY1113158T1 (el)	2002-03-07	2012-09-28	Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
CY2012031C CY2012031I1 (el)	2002-03-07	2012-12-14	Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
LU92117C LU92117I2 (fr)	2002-03-07	2012-12-19	Méthanesulfonate d'éthylester d'acide 3-[2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-proprionique
NO2013001C NO2013001I2 (no)	2002-03-07	2013-01-02	Dabigatran-etexilate og salter derav; spesielt dabigatran-etexilate-mesylate
US14/489,892 US20150005350A1 (en)	2002-03-07	2014-09-18	Administration of ethyl 3-[(2--1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US15/946,096 US20180221359A1 (en)	2002-03-07	2018-04-05	Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US16/380,161 US20190231766A1 (en)	2002-03-07	2019-04-10	Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US16/694,091 US20200085807A1 (en)	2002-03-07	2019-11-25	Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10209985A DE10209985A1 (de)	2002-03-07	2002-03-07	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Publications (1)

Publication Number	Publication Date
DE10209985A1 true DE10209985A1 (de)	2003-09-25

Family

ID=27771070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE10209985A Withdrawn DE10209985A1 (de)	2002-03-07	2002-03-07	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze

Country Status (4)

Country	Link
CN (1)	CN101632668A (uk)
DE (1)	DE10209985A1 (uk)
UA (2)	UA81760C2 (uk)
UY (1)	UY27694A1 (uk)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104414995A (zh) *	2013-09-04	2015-03-18	天津汉瑞药业有限公司	甲磺酸达比加群酯的药用组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6215239B2 (ja)	2012-02-21	2017-10-18	ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ	ダビガトランエテキシラートの経口医薬組成物
CN102793699B (zh) *	2012-08-06	2014-06-04	严轶东	一种含有达比加群酯的药用组合物
CN104825422B (zh) *	2014-09-29	2017-12-12	普济生物科技（台州）有限公司	含达比加群酯甲磺酸盐的药物组合物及其制备方法
CN105640909B (zh)	2014-11-14	2019-09-20	正大天晴药业集团股份有限公司	一种含有达比加群酯的药用组合物
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法

2002
- 2002-03-07 DE DE10209985A patent/DE10209985A1/de not_active Withdrawn
2003
- 2003-03-03 UA UA20041008096A patent/UA81760C2/uk unknown
- 2003-03-03 UA UAA200708221A patent/UA95601C2/uk unknown
- 2003-03-03 CN CN200910149806A patent/CN101632668A/zh active Pending
- 2003-03-06 UY UY27694A patent/UY27694A1/es not_active Application Discontinuation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104414995A (zh) *	2013-09-04	2015-03-18	天津汉瑞药业有限公司	甲磺酸达比加群酯的药用组合物

Also Published As

Publication number	Publication date
CN101632668A (zh)	2010-01-27
UY27694A1 (es)	2003-10-31
UA81760C2 (uk)	2008-02-11
UA95601C2 (uk)	2011-08-25

Publication	Publication Date	Title
EP1485094B2 (de)	2020-03-25	Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
DE10209982A1 (de)	2003-09-25	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE69833490T2 (de)	2006-10-19	Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung
DE69621523T2 (de)	2003-01-30	Verfahren zur herstellung einer pharmazeutischen formulierung
DE69832816T2 (de)	2006-08-31	Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DE69624907T2 (de)	2003-08-21	Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten
DE69533470T2 (de)	2005-09-22	Aus mehreren einzeleinheiten zusammengesetztes pharmazeutisches präparat, das einen protonenpumpeninhibitor enthält
EP1689370B1 (de)	2008-02-13	VERFAHREN ZUR HERSTELLUNG EINER FESTEN, ORAL APPLIZIERBAREN PHARMAZEUTISCHEN ZUSAMMENSETZUNG Mit 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE69630286T2 (de)	2004-07-22	Aus mehreren einzeleinheiten zusammengesetzte dosierungsformen enthaltend einem protonen pumpen inhibitor
DE69624910T2 (de)	2003-09-04	Orale pharmazeutische dosierungsformen die einen protonenpumpeninhibitor und ein prokinetisches mittel enthalten
US20030181488A1 (en)	2003-09-25	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CH648484A5 (de)	1985-03-29	Pharmazeutische zubereitung eines festen medikamentmaterials.
DE69721749T2 (de)	2004-03-25	Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung
DE102008046650A1 (de)	2010-03-11	Quetiapin enthaltende Retardtablette
WO2010043408A2 (de)	2010-04-22	Mikroverkapseltes fesoterodin
DE102008037324A1 (de)	2010-02-18	Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
DE60030654T2 (de)	2007-04-05	Verwendung von Lasofoxifen
DE10209985A1 (de)	2003-09-25	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE10245624A1 (de)	2004-04-08	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
EP1663162B1 (de)	2008-05-28	Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe
WO2011000518A1 (en)	2011-01-06	Pharmaceutical composition comprising desloratadine
DE60205925T2 (de)	2006-06-08	Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisochinol-2-yl)-5-(2-pyridyl)chinazolin
DE10152469A1 (de)	2003-06-26	3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
EP1424068A1 (de)	2004-06-02	Verfahren zur Herstellung von Pellets, enthaltend ein tri- oder tetracyclisches Antidepressivum sowie diese Pellets enthaltende pharmazeutische Zubereitungen
HK1135337A (en)	2010-06-04	Orally administered pharmaceutical composition

Legal Events

Date	Code	Title	Description
2009-06-04	8141	Disposal/no request for examination

DE10209985A1 - Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (64)

Applications Claiming Priority (1)

Publications (1)

Family

ID=27771070

Family Applications (1)

Country Status (4)

Cited By (1)

Families Citing this family (6)

Cited By (1)

Also Published As

Similar Documents

Legal Events